News

The latest from Cogstate – leaders in optimising the measure of cognition to guide decision-making.

Cogstate Announces Appointment of Jane McAloon to Board of Directors

January 30, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Jane McAloonas an Independent Non-Executive Director and, following release of the Appendix 4D Half Year Financial Report on 23 February 2017, Chair of the Audit & Compliance Committee of Cogstate Ltd. Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as […]

Cogstate Announces Appointment of Dr. Richard Mohs to Board of Directors

January 24, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director. Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard […]

Cognitive Decline and PTSD Symptoms Linked In Large Study Of Civilian Women

January 20, 2017

Living through a traumatic event is an unfortunate reality for many people with each episode resulting in varying recovery timelines and potentially long-term effects. When lasting effects result in daily challenges to normal activities, a diagnosis of post-traumatic stress disorder (PTSD) can trigger a treatment protocol of medications, counseling and support to help manage ongoing […]

Cogstate Announces New Executive Appointments For Clinical Trials And Healthcare Business Units

November 30, 2016

The cognitive science company, Cogstate Ltd (ASX.CGS) announced today two key appointments to executive positions. George Hunnewell has been named Chief Operating Officer of Cogstate and President of the Cogstate Clinical Trials division. Hunnewell, who previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, will be responsible for the company’s worldwide […]

High Blood Pressure In Children Negatively Impacts Cognitive Performance

November 16, 2016

According to the Centers for Disease Control and Prevention, obesity among U.S. children and adolescents (aged 2-19) remained high between 2011 and 2014 at about 17%. Of these approximately 13 million young people, almost 10% are also diagnosed with primary hypertension, risking long-term cardiovascular organ damage as they move into adulthood. Beyond its physical effects, […]

Study Finds Brexpiprazole To Be An Effective Alternative To Aripiprazole

November 8, 2016

Despite the number of available antipsychotics, schizophrenia is still a complicated brain disorder to treat, in part due to the different side effects of various treatment regimens between patients. Brexpiprazole, a serotonin-dopamine activity modulator approved by the FDA for schizophrenia in 2015, was developed by Otsuka as a successor to aripiprazole, whose U.S. patent expired […]

Cogstate and Clinical Ink Deliver Enhanced Tablet-Based eCOA for CNS Clinical Trials

October 24, 2016

New Haven, CT & Philadelphia, PA– October 25, 2016: Cognitive science company, Cogstate Ltd (ASX.CGS) and Clinical Ink, the leading provider of eSource and patient engagement technologies, today announced they have formalized their long-standing relationship with a strategic alliance that delivers enhanced tablet-based neuropsychological assessments for CNS clinical trials. The alliance combines, in a single […]

Cogstate Computerized Battery Effective For Long-Term Monitoring of Cognitive Side Effects in Pediatric Leukemia Patients

October 20, 2016

Children with acute lymphoblastic leukemia (ALL) often battle neurocognitive deficits as a result of their radiation or chemotherapy treatment. During treatment and sometimes up to two years after treatment, their quality of life is affected by impairments in attention, processing speed and executive functioning. While many pediatric leukemia studies have identified possible counter measures later […]

Study Highlights Correlation Between Cogstate Battery And Traditional Neuropsychological Tests

October 12, 2016

Detecting the earliest signs of cognitive decline in older adults provides clinicians and researchers with opportunities to study the beginning stages of dementia, particularly Alzheimer’s disease (AD). Some traditional “paper and pencil” neuropsychological tests provide accuracy and a rich database of historical studies, but they can also present challenges such as ensuring standardized administration, cultural […]

Study Confirms Biomarkers Combined With Sensitive Cognitive Tests Are Important For Identifying Early Stage Alzheimer’s Disease

September 24, 2016

After more than ten years, the amyloid cascade hypothesis of Alzheimer’s disease (AD) is still at the core of new research findings. By proposing that AD starts with the accumulation of beta amyloid (Aβ) protein plaques in the brain, which may lead to the twisted tangles of the tau protein, researchers have focused on the […]

Subjective Memory Decline Shown To Be Early Warning Sign Of Cognitive Disease

September 9, 2016

The first signs of cognitive decline among older adults are often memory-related. Forgetting a name, misplacing objects, or not remembering prior conversations becomes more common over the age of 50, sometimes leading to concerns that this forgetfulness is more than just normal aging. Known as subjective memory decline (SMD), researchers are asking if these episodes […]

Research Finds Neurodegeneration In The Absence Of Beta Amyloid Is Not Associated With Cognitive Decline

August 30, 2016

As we age, our brains inevitably change just as the rest of our bodies do. Once past 60 years old, some of those changes can become noticeable in our daily lives such as small slips of memory. With the increasing information available on Alzheimer’s disease, dementia and other age-related cognitive decline, those signs can cause […]

Computerised Cognitive Test Battery Matches Gold Standard for HAND Screening

July 8, 2016

Besides enduring the challenges of HIV infection, 20-50% of patients also experience cognitive decline, including difficulty with attention, memory and executive functions. Diagnosed as HIV-associated neurocognitive disorder (HAND), the symptoms can cause difficulty with everyday work/life tasks and may progress to more severe limitations over time. Standard neuropsychological (NP) tests can identify the three categories […]

Study Suggests Dementia After CABG Surgery Is Not Related To POCD

May 28, 2016

Over 15 years ago, a groundbreaking study found that over 40% of patients who had undergone coronary artery bypass graft (CABG) surgery still showed signs of cognitive impairment five years later. Grouped under the blanket diagnosis of postoperative cognitive disorder (POCD), some researchers question whether the surgery itself caused the impairment or the underlying cardiovascular […]

Understanding Cognitive Decline In Breast Cancer Patients Treated With Endocrine Therapy

May 14, 2016

While there will be almost a quarter million new diagnoses of breast cancer this year in the U.S., the percentage of survivors has been on the rise since 1989. Treatment regimens that include chemotherapy and adjuvant endocrine therapies have been proven effective for hormone receptor positive patients. Specifically, two recent clinical trials, TEXT and Suppression […]

1 2 3 7